Am J Transplant, Volume 20, Suppl 3 Archives - Page 84 of 223 - ATC Abstracts

2020 American Transplant Congress
Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study
K. Shinoda¹, H. Oguchi¹, K. Nishikawa¹, T. Yonekura¹, M. Muramatsu¹, T. Kawamura¹, Y. Hamasaki¹, T. Mikami², K. Sakai¹, S. Shishido¹
¹Toho University Faculty of Medicine, Tokyo, Japan, ²Pathology, Toho University Faculty of Medicine, Tokyo, Japan
*Purpose: The purpose of this study is to explore the risk factors associated with the development of chronic active antibody mediated rejection (CAAMR) after the…
2020 American Transplant Congress
Comparing Surgical and Urological Complications Over Time in Deceased Donor Kidney Transplantation
A. Mekhaimar, H. Maple, N. Mamode, R. H. Zakri, N. Kessaris
King's College London/Guy's and St Thomas' Hospital, London, United Kingdom
*Purpose: Despite advances in perioperative and post-transplant management over time, complications still occur following deceased donor (DD) kidney transplantation. This study aimed to determine the…
2020 American Transplant Congress
Discontinuation Rates in Multicenter Trials – Are They Driven by Attitudes or Facts?
B. Nashan¹, F. Braun², D. Dragun³, I. A. Hauser³, P. Schemmer², H. J. Schlitt², C. Sommerer³, B. Suwelack³, C. Schiedel⁴, I. Kroeger⁴, F. Thaiss³
¹Athena and Hephaistos, Study Group, Germany, ²Hephaistos, Study Group, Germany, ³Athena, Study Group, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
*Purpose: The ATHENA [NCT01843348] and Hephaistos [NCT01551212] trials were designed to compare everolimus [EVR] in combination with reduced tacrolimus [rTAC] or reduced cyclosporine A [rCyA]…
2020 American Transplant Congress
Patients in Donor Service Areas with Higher Median MELD at Transplant Have a Lower Probability of Liver Transplant Waitlist Activation
J. Merola¹, S. Noreen², D. Stewart², R. Batra¹, D. Haakinson¹, G. Gan³, Y. Deng³, S. Kulkarni¹
¹Yale School of Medicine, New Haven, CT, ²United Network of Organ Sharing, Richmond, VA, ³Yale Center for Analytical Sciences, Yale University, New Haven, CT
*Purpose: US allocation of hepatic allografts is prioritized based on medical need, however significant geographical disparities exist with median MELD at transplant across donor specific…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
A. K. Mezochow, P. L. Abt, T. Bittermann
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…
2020 American Transplant Congress
Effect of Pre-Transplant Opioid Use on Post Liver Transplant Outcomes
K. Guilbert, H. Underwood, C. J. Simon
Lahey Hospital and Medical Center, Burlington, MA
*Purpose: Impact of pre-liver transplant opioid use on post-liver transplant length of stay and clinical outcomes.*Methods: This single-institution retrospective study included adult patients who received…
2020 American Transplant Congress
Vira-ome: A Tool for an Unbiased Plasma Virome Analysis of SOT Recipients from Cell-Free DNA Sequences
R. Sinha, E. Bixler, J. Grantham, M. Altrich, S. Kleiboeker
R&D, Viracor-Eurofins, Lee's Summit, MO
*Purpose: Blood virome of healthy individuals is frequently predominated by member of families such as Herpesvirus, Anellovirus and Polyomaviridae. The viral load of commensal species…
2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
J. M. Steinbrink, J. Byrns, L. Crona, M. Ellis, S. Sanoff, E. K. Maziarz, C. R. Wolfe
Duke University, Durham, NC
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…
2020 American Transplant Congress
Organ and Tissue Donation Education for Transplant Patients Staying at a Transplant Hospitality House Leads to Successful Cornea Donation
T. Giordano¹, L. Suplee², J. L. Weinstock³, R. D. Hasz⁴, H. M. Nathan⁵
¹Family Support Manager, Caregiver Lifeline Program, Gift of Life Family House, Philadelphia, PA, ²Director, Transplant Information Center, Gift of Life Donor Program, Philadelphia, PA, ³Vice President and General Counsel, Gift of Life Donor Program, Philadelphia, PA, ⁴Vice President of Clinical Services, Gift of Life Donor Program, Philadelphia, PA, ⁵President and CEO, Gift of Life Donor Program, Philadelphia, PA
*Purpose: A transplant hospitality house (THH) serving multiple transplant centers is directly connected to its region’s Organ Procurement Organization (OPO) and offers formal education to…